ライフサイエンスコーパス: 5-HT4 receptor

1 ta-arrestin-independent Erk1/2 activation by 5-HT4 receptor.

2 ng >5 h in slice recordings, mediated by the 5-HT4 receptor.

3 ng of the physiology and pharmacology of the 5-HT4 receptor.

4 ort-circuit current via submucosal 5-HT3 and 5-HT4 receptors.

5 ed that the effects of 5-HT were mediated by 5-HT4 receptors.

6 activation stimulated DBS via muscarinic and 5-HT4 receptor activation.

7 induces HCO3(-) secretion via muscarinic and 5-HT4 receptor activation.

8 region that mediates the effect of enhanced 5-HT4 receptor activity and CK2 as modulator of 5-HT4 re

9 and benzimidazolone series possessed greater 5-HT4 receptor affinity than the corresponding indole an

10 e serotonin (5-HT)2C receptor antagonists, a 5-HT4 receptor agonist, a 5-HT7 receptor antagonist, NMD

11 led to the development of several selective 5-HT4 receptor agonists and antagonists that may have th

12 In support, 5-HT2 and 5-HT4 receptor agonists mimicked the facilitating effect

13 ne moiety increased, the selectivity for the 5-HT4 receptor also increased.

14 e of forming hydrogen bonds showed increased 5-HT4 receptor antagonist activity.

15 5-HT4 receptor antagonist affinity was further increased

16 le-3- carboxamide) as a potent and selective 5-HT4 receptor antagonist with clinically suitable pharm

17 SB204070, a selective 5-HT4 receptor antagonist, dose-dependently reduced lumi

18 nificantly attenuated by selective 5-HT2 and 5-HT4 receptor antagonists, but not by a 5-HT3 receptor

19 an acyclic aminoalkylene chain led to potent 5-HT4 receptor antagonists.

20 Serotonin 5-HT4 receptors are promising candidates in IBS pathophy

21 DD, there was a correlation between cerebral 5-HT4 receptor binding and verbal memory (r = 0.29; P =

22 In addition, the association between 5-HT4 receptor binding and verbal memory performance in

23 outcome was the group difference in cerebral 5-HT4 receptor binding between patients with MDD and hea

24 current MDD had significantly lower cerebral 5-HT4 receptor binding than healthy controls (-7.0%; 95%

25 Results of this study show that cerebral 5-HT4 receptor binding was lower in patients with MDD th

26 th [11C]SB207145 for quantification of brain 5-HT4 receptor binding, but only the patients underwent

27 with MDD was associated with lower cerebral 5-HT4 receptor binding.

28 m (SNP) (rs201253747) c.*61 T > C within the 5-HT4 receptor gene HTR4 to be predominantly present in

29 MDD), and pharmacological stimulation of the 5-HT4 receptor has been associated with improved learnin

30 The 5-HT4 receptor has emerged as a new therapeutic target s

31 In the alimentary tract, stimulation of 5-HT4 receptors has a pronounced effect on smooth muscle

32 Importantly, prolonged activation of 5-HT4 receptor in COS-7 cells or prolonged treatment of

33 rtantly, it is sufficient to overexpress the 5-HT4 receptor in the mPFC to generate mice with a simil

34 and evaluated for antagonist affinity at the 5-HT4 receptor in the rat esophagus.

35 dentifying the role of 5-hydroxytryptamine4 (5-HT4) receptors in the initiation of the peristaltic re

36 The 5-HT4 receptor is a member of the seven transmembrane sp

37 The cerebral 5-HT4 receptor is a promising treatment target for memor

38 The 5-HT4 receptor is pharmacologically defined by selective

39 Here we show that the 5-HT4 receptor is regulated by CK2, at transcriptional a

40 The cerebral serotonin 4 (5-HT4) receptor is a promising novel target for treatmen

41 T4 receptor activity and CK2 as modulator of 5-HT4 receptor levels in this brain region that regulate

42 In the urinary bladder, activation of 5-HT4 receptors modulates cholinergic/purinergic transmi

43 eptor mRNA but frequently expressed 5-HT1 or 5-HT4 receptor mRNA.

44 In the heart, stimulation of atrial 5-HT4 receptors produces positive inotropy and tachycard

45 ibition, whereas specific 5-HT3 (Y-25130) or 5-HT4 receptor (RS39604) antagonist failed to block the

46 In vivo, 5-HT4 receptor signaling is also upregulated since ERK a

47 5-HT4 receptor signaling is enhanced in vitro, as eviden

48 In the adrenal gland, agonism of 5-HT4 receptors stimulates release of cortisol, corticos

49 -mediated pathways involving either 5-HT3 or 5-HT4 receptor subtype.

50 Short-term activation of a serotonin 5-HT4 receptor that is coupled to G alpha13 also increas

51 this regulation is region-specific, with the 5-HT4 receptor upregulated in prefrontal cortex (PFC) bu

52 The involvement of 5-HT4 receptors was examined with selective 5-HT4 agonis